



Scale Smarter From First-in-Human to Market



The Challenge

For emerging biologics, Phase I is just the beginning. If your early data looks promising, you'll need a partner who can handle the next steps, without forcing a complete manufacturing reset.

The KBI Biopharma Advantage



Seamless, Flexible Scale-Up

Start small for FIH, scale up for Phase II and beyond in the same bioreactor, all under one CDMO umbrella.



Faster Phase Progression

Our integrated process design workflows from CLD to GMP accelerate each production milestone.



Complete Global Support

With US-based manufacturing hubs and development facilities in the US and Europe, we're well - placed to meet any global regulatory or supply chain needs.

Designed for the Long Haul



Robust Cell Line Foundation

Selexis® CHO-M with transposase-mediated semi-targeted integration yields flexible, high-yield clones that adapt to larger bioreactors with minimal re-optimization.



A Partner that Grows with You

The same CDMO from FIH to commercial means you keep your data, process, and proven team.



Future-Ready

We're set up to handle complex molecules (bispecifics, Fc-fusions, next-gen mAbs, and more) so you never have to outgrow our capabilities.



Get In Touch

Ready to future-proof your FIH biologic's development journey?

Talk to us about how industry-recognized CLD, powered by Selexis®, and advanced manufacturing capabilities can drive your molecule from concept to commercialization, hassle-free.



A JSR Life Sciences Company